Literature DB >> 16397277

The magnetic resonance imaging contrast agent mangafodipir exerts antitumor activity via a previously described superoxide dismutase mimetic activity.

Jan Olof G Karlsson, Heidi Brurok, Rob Towart, Per Jynge.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16397277     DOI： 10.1158/0008-5472.CAN-05-2053

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  3 in total

1.  First clinical experience with the magnetic resonance imaging contrast agent and superoxide dismutase mimetic mangafodipir as an adjunct in cancer chemotherapy-a translational study.

Authors:  Jan Olof G Karlsson; Karin Adolfsson; Bo Thelin; Per Jynge; Rolf Gg Andersson; Ursula G Falkmer
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

2.  Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer Activity.

Authors:  Tino Kurz; Derek Grant; Rolf Gg Andersson; Robertson Towart; Michelandrea De Cesare; Jan Olof G Karlsson
Journal:  Transl Oncol       Date:  2012-08-01       Impact factor: 4.243

3.  Superior therapeutic index of calmangafodipir in comparison to mangafodipir as a chemotherapy adjunct.

Authors:  Jan Olof G Karlsson; Tino Kurz; Susanne Flechsig; Jacques Näsström; Rolf Gg Andersson
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.